Reproductive performance in dairy cows with cystic ovarian disease after single treatment with buserelin acetate or dinoprost

Gonadotropin-Releasing Hormone (GnRH) and Its Agonists in Bovine Reproduction II: Diverse Applications during Insemination, Post-Insemination, Pregnancy, and Postpartum Periods

The administration of GnRH and its agonists benefits various aspects of bovine reproductive programs, encompassing physiological stages such as estrous synchronization, post-insemination, pregnancy, and the postpartum period. The positive impact of GnRH administration in overcoming challenges like repeat breeder cows, early embryonic loss prevention, and the management of cystic ovarian disease (COD) is thoroughly surveyed. Furthermore, this review focuses on the significance of GnRH administration during the postpartum period, its role in ovulation induction, and how it enhances the productivity of embryo transfer (ET) programs. An emerging feature of this field is introduced, focusing on nano-drug delivery systems for GnRH agonists, and the potential benefits that may arise from such advancements are highlighted. While this review offers valuable insights into various applications of GnRH in bovine reproduction, it emphasizes the crucial need for further research and development in this field to advance reproductive efficiency and health management in dairy cattle.

Effect of Double-Ovsynch and Presynch-Ovsynch on postpartum ovarian cysts and inactive ovary in high-yielding dairy cows

Introduction

Optimizing the management of dairy cattle reproduction can reduce postpartum ovarian disease in high-yielding dairy cows and thus enhance ranch economic benefit. The hypothesis of this study was that the Double-Ovsynch (DO) protocol in high-producing dairy cows would result in a lower incidence of follicular cysts but a higher incidence of luteal cysts compared to those undergoing the Presynch-Ovsynch (PS) protocol.

Methods

In this experiment, 384 cows (204 primiparous and 180 multiparous) were allocated to the DO group, which followed the protocol: GnRH-7d-PGF2α-3d-GnRH-7d-Ovsynch-56 h (GnRH-7d-PGF2α-56 h-GnRH-16hTAI), starting on 39 ± 3 days in milk (DIM). Additionally, 359 cows (176 primiparous and 183 multiparous) were assigned to the PS group, which followed the protocol: PGF2α-14d-PGF2α-12d-Ovsynch-56 h, starting on 31 ± 3 DIM. In DO, B-mode ultrasound examinations were conducted 1 day after the GnRH-7d-PGF2α-3d-GnRH protocol to diagnose the presence of ovarian diseases followed by reexamination after 7 days of suspected cases. In PS, B-mode ultrasound examinations were conducted 1 day after the PGF2α-14d-PGF2α protocol to diagnose the presence of ovarian diseases followed by reexamination after 7 days. For all cows confirmed to having ovarian diseases, a second B-mode ultrasound examination was conducted at the time of the second GnRH and timed artificial insemination (TAI). If the ovary showed a normal developing follicle in combination with normal ovulation, the ovarian disease was considered to be cured.

Results

The current study revealed no significant difference in the overall incidence and cure rate of postpartum ovarian diseases between DO and PS (incidence rate: 3.9% vs. 6.7%, cure rate: 50% vs. 41.7%, DO vs. PS). Also, there was no significant difference in the incidence and cure rate of luteal cysts between DO and PS (incidence rate: 2.9% vs. 2.2%, cure rate: 50.0% vs. 50.0%). The incidence of follicular cysts was significantly lower in the DO group than in the PS group (0.8% vs. 2.8%, DO vs. PS, p = 0.037), but there was no significant difference in the cure rates (66.7% vs. 50%). The occurrence of inactive ovary was lower in DO compared to PS (0.2% vs. 1.7%, p = 0.047). There was no significant difference in the pregnancy rate between the DO and PS groups (48.2% vs. 41.8%), although the DO group had a higher rate. What is different from our assumption is that PS did not effectively reduce the incidence of postpartum luteal cysts.

Application of Exogenous GnRH in Food Animal Production

Over several decades, exogenous GnRH and agonists have been employed for controlling reproductive cascades in animals, and treating some reproductive morbidities. The administration of GnRH is used in animals to counter ovarian dysfunction, induce ovulation, and to increase conception and pregnancy rates. GnRH and its agonists are used in the treatment of cystic ovarian degeneration and repeat breeder syndrome. The development of protocols for GnRH administration by intramuscular injection, intramuscular or subcutaneous implants, and intravaginal deposition has empowered their clinical use worldwide. Currently, exogenous GnRH products are a central part of several pre- and post-breeding programs for the enhancement of fertility, including the control of estrous cycles and timing of ovulation, development of fixed-time artificial insemination protocols, improved embryo survival, and the treatment of reproductive morbidity. The aim of the present review is to summarize the application of exogenous GnRH agonists in food animal production.

Early Warning for Ovarian Diseases Based on Plasma Non-esterified Fatty Acid and Calcium Concentrations in Dairy Cows

Inactive ovaries (IO) and ovarian (follicular or luteal) cysts (FC or LC) are two common ovarian diseases leading to infertility in dairy cattle. Both disorders are associated with altered metabolites and hormones. There are currently no known effective biomarkers that can be used for early diagnosis of ovarian diseases. The purpose of this study was to identify the plasma biomarkers of ovarian diseases in Holstein dairy cows that facilitate an early diagnosis of the diseases and control its progression. The experiment was performed from 3 weeks postpartum and last for 7 weeks. Seventy-six multiparous Holstein cows (mean age, 4.36 years; weight, 635.63 kg) were divided into healthy control group (HC, n = 22), FC group (n = 18), LC group (n = 18) and IO group (n = 18) by rectal palpation or ultrasonography during the last 2 weeks before trial end. Blood was collected via tail vein for measurement of plasma energy metabolites, liver function indicators, minerals, and hormones at 3 and 8 weeks postpartum. Data were analyzed by Mann-Whitney U, Kruskal-Wallis, Spearman correlation, binary logistic regression analysis and receiver operating characteristic analysis, where applicable. At 8 weeks postpartum, FC cows had a more severe body condition score loss and these had greater levels of non-esterified fatty acids (NEFA) and estradiol, and lesser levels of alanine aminotransferase (ALT), progesterone and insulin-like growth factor 1 (IGF-1) levels than HC cows (P < 0.05). LC cows had a lower milk yield, higher NEFA and progesterone levels, and lower calcium, phosphorus and magnesium levels than HC cows (P < 0.05). IO cows had a lower body condition score, higher NEFA levels, and lower ALT, calcium, phosphorus, magnesium, estradiol, progesterone and IGF-1 levels than HC cows (P < 0.05). At 3 weeks postpartum, cows with ovarian diseases had greater (P < 0.05) concentrations of NEFA, and lesser concentrations of ALT, calcium, phosphorus and IGF-1 than HC cows. Early warning values for ovarian diseases were plasma NEFA concentrations >0.50 mmol/L, or calcium concentrations <2.02 mmol/L. Therefore, plasma NEFA and calcium could be used as early-warning indicators for ovarian diseases in dairy cows.

Cystic ovary disease impairs transport speed, smooth muscle contraction, and epithelial ion transport in the bovine oviduct

Cystic ovary disease (COD) is a common cause of bovine infertility but the impact of this disease on the oviduct is unknown. The aim of this study was to analyze the effects of COD on particle transport speed (PTS), ciliary beat frequency, myosalpinx contraction, and epithelial ion transport. Oviducts were obtained from cows affected by COD and compared with those of healthy, mid-diestrus cows. PTS and CBF were examined using live-cell imaging. Smooth muscle contraction and epithelial ion transport were investigated using organ baths and Ussing chambers. Our results showed that muscarinic receptors are involved in cholinergic signaling in the oviduct and that forskolin-induced cyclic AMP production is involved in active ion transport in the oviductal epithelium. Oviducts from cows with luteal cysts revealed significantly decreased PTS (p = 0.02). Further to that, in the oviducts of COD cows, the cholinergic regulation of smooth muscle contractions and active epithelial ion transport were significantly diminished (p < 0.0001). These results imply that in COD cows, oviductal transport is compromised by decreased fluid flow speed and reduced cholinergic regulation of smooth muscle contraction and ion transport. This knowledge contributes to a more comprehensive understanding of COD supporting the development of novel therapeutic concepts for infertility treatment.

Ovarian cysts, an anovulatory condition in dairy cattle

Ovarian cysts are one of the most common ovarian dysfunctions in dairy cattle, which can lead to a considerable economic loss through its high incidence and can reduce the reproductive performance. Anestrus is the most significant clinical sign observed in dairy cattle suffering from this condition. For diagnosis, most of the veterinarians use a combination of methods, from ultrasonography as an additional approach to trans-rectal palpation and symptomatology when assessing ovarian cysts. Although the Ovsynch treatment seems to be preferred, the pregnancy rate after this treatment is relatively low. Despite such reports on dairy cattle ovarian cysts, the data is insufficient to validate all the characteristics of this condition. This review summarizes what the literature has so far provided from definition to treatment of ovarian cysts in dairy cattle.

Expression and localisation of epidermal growth factor receptors and their ligands in the lower genital tract of cycling cows

The epidermal growth factor receptor (ErbB) family and its ligands are essential for the regulation of multiple cellular processes required for mammalian reproduction. The objectives of this study were to investigate the expression and localisation of ErbB subtypes (ErbB1-4) and selected ligands, namely epidermal growth factor (EGF), amphiregulin (AREG) and neuregulin (NRG), in the cervix and vagina of cycling cows and to determine possible steroid hormone-dependence of their expression using immunohistochemistry. All four ErbBs and EGF, AREG and NRG proteins were found to be localised in the nucleus and cytoplasm of different cells in the cervix and vagina, and their expression differed during the oestrous cycle. During the follicular phase, in both the cervix and vagina, ErbB1, ErbB2, ErbB3, ErbB4 and EGF expression was higher in the luminal epithelium (LE) than in stromal and smooth muscle (SM) cells (P<0.05). During the luteal phase, the expression of ErbB1, ErbB3 and EGF in the LE was significantly different from that in stromal and SM cells in the cervix, whereas the expression of EGF and AREG differed in the vagina compared to the cervix (P<0.05). Throughout the oestrous cycle, in both the cervix and vagina, although ErbB2/human epidermal growth factor receptor 2 expression in the LE and SM cells was significantly higher than in the stromal cells (P<0.05), NRG expression was similar in the LE, stromal and SM cells (P>0.05). Overall, these results suggest that all four ErbBs and the EGF, AREG and NRG proteins may collectively contribute to several cellular processes in the bovine cervix and vagina during the oestrous cycle.